ACRV
Acrivon Therapeutics, Inc.Company with tickers: ACRV
CIK
1781174
CUSIP
004890109
Shares Outstanding
42,801,729
Website
https://acrivon.com/
13F Activity (30d)
2 filings
1 filers
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Charles Baum, M.D., Ph.D. | Class I Director | Appointed | 2026-06-17 |
| Michael Tomsicek, M.B.A. | Class I Director | Appointed | 2026-06-17 |